Pfizer Inc. $PFE Holdings Cut by Prospera Financial Services Inc

Prospera Financial Services Inc reduced its stake in Pfizer Inc. (NYSE:PFE) by 39.8% in the third quarter, HoldingsChannel.com reports. The fund owned 107,972 shares of the biopharmaceutical company’s stock after selling 71,421 shares during the quarter. Prospera Financial Services Inc’s holdings in Pfizer were worth $2,752,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares during the last quarter. Geode Capital Management LLC lifted its stake in Pfizer by 1.4% in the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after buying an additional 1,820,634 shares during the last quarter. Norges Bank acquired a new position in shares of Pfizer during the second quarter valued at $2,270,157,000. Charles Schwab Investment Management Inc. grew its position in shares of Pfizer by 2.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after acquiring an additional 1,135,457 shares during the last quarter. Finally, Fisher Asset Management LLC grew its position in shares of Pfizer by 2.0% during the second quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock worth $1,172,980,000 after acquiring an additional 950,239 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 1.0%

Pfizer stock opened at $27.47 on Friday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The stock has a market capitalization of $156.16 billion, a PE ratio of 20.19 and a beta of 0.47. The firm has a 50 day simple moving average of $25.77 and a 200-day simple moving average of $25.17.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is presently 126.47%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Post-earnings bullishness: unusual call-option activity and an upbeat earnings outlook have put some investors on the buy side, supporting short-term sentiment. Read More.
• Positive Sentiment: Investor commentary sees a buying opportunity after the quarter — analysts and commentators highlight attractive valuation and the company’s ability to generate cash as reasons to consider PFE after results. Read More.
• Positive Sentiment: Capital return profile: coverage notes Pfizer returned about $9.8B to shareholders and remains a high-yield candidate for income investors, which supports the stock’s floor for dividend-seeking buyers. Read More. Read More.
• Positive Sentiment: Dividend/yield appeal: Pfizer appears on lists of high-yield dividend names, attracting income-focused investors even as growth questions persist. Read More.
• Neutral Sentiment: Longer-term growth outlook is mixed — analyses examine whether newly acquired and in‑pipeline drugs can offset a looming 2026–2030 patent cliff; outcome will determine medium-term revenue trajectory. Read More.
• Neutral Sentiment: “Is now the best time to buy?” pieces suggest re-evaluating Pfizer after earnings — these are informative to investors but stop short of a consensus buy/sell signal. Read More.
• Negative Sentiment: Analyst downgrade: Daiwa cut Pfizer from “outperform” to “neutral” and set a $27 price target, signaling limited near-term upside from their perspective and adding downward pressure. Read More.
• Negative Sentiment: Valuation / structural concerns: opinion pieces argue Pfizer could be a value trap if new product flow and M&A don’t offset fading COVID-era sales and patent expiries, which raises caution among some investors. Read More.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Scotiabank started coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. UBS Group initiated coverage on Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective for the company. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.00.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.